Company News
Coloplast Lowers FY Guidance Amid Kerecis Setback
Coloplast cut FY 2025/26 organic sales growth outlook to 5‑6% and EBIT growth to ~5% due to Kerecis setbacks and weak EU wound care.
Q2 2025/26 delivered 6% organic sales and 6% currency‑adjusted EBIT
